



University of Bradford eThesis

This thesis is hosted in [Bradford Scholars](#) – The University of Bradford Open Access repository. Visit the repository for full metadata or to contact the repository team



© University of Bradford. This work is licenced for reuse under a [Creative Commons Licence](#).

ABSTRACT

The rational design of drug crystals to facilitate particle size reduction

Mohammad Hossain SHARIARE B.Pharm (Hons.)

Keywords: Crystallisation, micronisation, particle size and morphology, mechanical properties, crystallinity, surface free energy, dissolution, aerodynamic characteristics, molecular modelling.

Micronisation of active pharmaceutical ingredients (APIs) to achieve desirable quality attributes for formulation preparation and drug delivery remains a major challenge in the pharmaceutical sciences. It is therefore important that the relationships between crystal structure, the mechanical properties of powders and their subsequent influence on processing behaviour are well understood. The aim of this project was therefore to determine the relative importance of particle attributes including size, crystal quality and morphology on processing behaviour and the characteristics of micronised materials. It was then subsequently intended to link this behaviour back to crystal structure and the nature of molecular packing and intermolecular interactions within the crystal lattice enabling the identification of some generic rules which govern the quality of size reduced powders. In this regard, different sieve fractions of lactose monohydrate and crystal variants of ibuprofen and salbutamol sulphate (size, morphology and crystal quality) were investigated in order to determine those factors with greatest impact on post-micronisation measures of particle quality including particle size, degree of crystallinity and surface energy.

The results showed that smaller sized feedstock should typically be used to achieve ultrafine powders with high crystallinity. This finding is attributed to the reduced number of fracture events necessary to reduce the size of the particles leading to decreases in milling residence time. However the frequency of crystal cracks is also important, with these imperfections being implicated in crack propagation and brittle fracture. Ibuprofen crystals with a greater number of cracks showed a greater propensity for comminution. Salbutamol sulphate with a high degree of crystal dislocations however gave highly energetic powders, with reduced degree of crystallinity owing to the role dislocations play in facilitating plastic deformation, minimising fragmentation and extending the residence of particles in the microniser. Throughout these studies, morphology was also shown to be critical, with needle like morphology giving increased propensity for size reduction for both ibuprofen and salbutamol sulphate, which is related to the small crack propagation length of these crystals. This behaviour is also attributed to differences in the relative facet areas for the different morphologies of particles, with associated alternative deformation behaviour and slip direction influencing the size reduction process. Molecular modelling demonstrated a general relationship between low energy slip planes, d-spacing and brittleness for a range of materials, with finer particle size distributions achieved for APIs with low value of highest d-spacings for identified slip planes. The highest d-spacing for any material can be readily determined by PXRD (powder x-ray diffraction) which can potentially be used to rank the milling behaviour of pharmaceutical materials and provides a rapid assessment tool to aid process and formulation design.

These studies have shown that a range of crystal properties of feedstock can be controlled in order to provide micronised powders with desirable attributes. These include the size, morphology and the density of defects and dislocations in the crystals of the feedstock. Further studies are however required to identify strategies to ensure inter-batch consistency in these attributes following crystallisation of organic molecules.

Published Work

Sections of the work in this thesis have previously been published or presented in the following form –

Publications as Research Papers

- Shariare, M.H., De Matas, M., York, P. & Shao, Q. (2011) **“The impact of material attributes and process parameters on micronisation of lactose monohydrate”**. *Int. J. Pharm.* 408, pp. 58-66.
- Shariare, M.H., De Matas, M. & York, P. (2011) **“Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate”**. *Int. J. Pharm.* 2011, 415: 62-72.
- Shariare, M.H., Leusen, F.J.J., De Matas, M., Anwar, J. & York, P. (2011) **“Prediction of the mechanical behaviour of active pharmaceutical ingredients”**. *Pharm. Res.* 2011.
- Shariare, M.H., Blagden, N., De Matas, M. & York, P. (2011) **“Influence of solvent properties on the morphology of ibuprofen crystals and its impact on particle size reduction”**. *J. Pharm Sci.* (In Press).

Oral Presentation

- **“A rapid method for predicting the mechanical behaviour of active pharmaceutical ingredients”**, Presented at CMP seminar, University of Bradford, UK, March, 2011.
- **“Towards a rapid method for predicting the mechanical behaviour of active pharmaceutical ingredients”**, Presented at **APS Materials by design**, University of Nottingham, UK, June 22-23, 2011.
- **“Milling to achieve the appropriate particle properties for inhalation, how can we rank or predict?”** Presented at ‘*APS Inhalation*’ University of Bath, UK, July 4-6, 2011.
”**Best poster presentation award from the selected abstract “**

Poster Presentation

- Shariare, M.H., De Matas, M., York, P. & Shao, Q. (2009) **“Particle optimisation for enhanced respiratory drug delivery”**. Presented at British Pharmaceutical Conference (BPC) 2009 and Published in *J. Pharm. Pharmacol.*, special issue: BPC conference, 2009.
- Shariare, M.H., Blagden, N., De Matas, M., Leusen, F.J.J. & York, P. (2010). **“Influence of crystallisation conditions on the morphology of ibuprofen crystals”**. Presented at UKPharmSci conference 2010 and published in *J. Pharm. Pharmacol.*, 62 (10), 1337.

- Shariare, M.H., De Matas, M., York, P. & Shao, Q. (2009) **“Particle process optimisation for enhanced respiratory drug delivery”**. Presented at American Association of Pharmaceutical scientists (AAPS), 2009.
- Shariare, M.H., Blagden, N., De Matas, M., Leusen, F.J.J. & York, P. (2010). **“Influence of solvent properties on the morphology of Ibuprofen crystals and its impact on particle size reduction”**. Presented at FIP Pharmaceutical Sciences world congress in association with American Association of Pharmaceutical scientists (AAPS) 2010.
- Shariare, M.H., Blagden, N., De Matas, M. & York, P. (2010) **“The Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronized salbutamol sulphate delivered by DPI”**. Presented at “Drug deliver to the lung 21” organised by The Aerosol Society, December, 2010. *J. Aerosol Med.* (In press).
- Shariare, M.H., Blagden, N., De Matas, M. & York, P. (2010) **“The impact of morphology and process parameters on micronisation of salbutamol sulphate”** Presented at EuPAT 4 conference, Kuopio, Finland, 2010.

Acknowledgement

I would like to express my gratitude and special thanks to my supervisors Prof. Peter York, Dr. Marcel de Matas, Dr. Nick Blagden and Dr. F.J.J. Leusen for their inspiration, support and guidance throughout the period of this research. I would also like to thank Prof. Jamshed Anwar for his helpful comments and guidance.

I would like to acknowledge the lactose samples supplied by DMV –Fonterra, Netherlands and salbutamol sulphate sample supplied by Cipla, India. I am indebted to the technical and secretarial staff within the School of Life Sciences. I would like to thank Dr. Wendy Hulse for her support during this study. I would also like to thank the school of life sciences purchasing department for their help, in particular A.K. Tucny for her support throughout the research work.

Finally I must appreciate the help of all my friends in IPI, University of Bradford for their encouragement and help.

**I dedicate this thesis
to my Mum, Dad and Wife (Shimu)
with thanks
for their unfailing love,
support and encouragement**

particle size reduction	
1.2.4.5. Effect of polymorphism on particle size reduction	24
1.3. Crystallisation of Solids	24
1.3.1. Supersaturation	25
1.3.2. Nucleation	27
1.3.3. Crystal growth	28
1.3.4. Factors affecting crystallisation	31
1.3.4.1. Induction time	31
1.3.4.2. Effect of cooling rate and supersaturation	32
1.3.4.3. Effect of agitation intensity	32
1.3.4.4. Solvent effects	33
1.3.4.5. Effects of impurities	34
1.4. Aims and objectives	34
1.5. Rational for selection of model compounds	37
1.6. Thesis structure	39
2. <u>General Materials and Methods</u>	
2.1. General materials	41
2.1.1. Probes for IGC	41
2.1.1.1. Non-polar probes	41
2.1.1.2. Polar probes	41
2.1.2. Materials for IGC column preparation	42
2.1.3. Equipment	42
2.2. General methods	43
2.2.1. Micronisation	43
2.2.2. Freeze drying	45
2.2.3. Particulate analysis	46
2.2.3.1. Particle size distribution	46
2.2.3.2. Scanning electron microscopy (SEM)	47
2.2.4. Thermal analysis	48

2.2.4.1.	Thermogravimetric analysis (TGA)	48
2.2.4.2.	Differential scanning calorimetry (DSC)	49
2.2.5.	Structural analysis	51
2.2.5.1.	Powder x-ray diffractometry (PXRD)	51
2.2.6.	Solid surface state characterisation	52
2.2.6.1.	Dynamic vapour sorption (DVS)	52
2.2.6.2.	Inverse gas chromatography (IGC)	54
3.	<u>The impact of material attributes and process parameters on micronisation of lactose monohydrate</u>	
3.1.	Introduction	60
3.2.	Materials	61
3.3.	Methods	61
3.3.1.	Andersen cascade impactor	61
3.3.2.	Sieving	62
3.3.3.	Micronisation	62
3.4.	Results and discussions	65
3.4.1.	Thermal and structural analysis	65
3.4.2.	Particle size distribution	72
3.4.3.	Surface analysis	78
3.4.3.1.	Dynamic vapour absorption	78
3.4.3.2.	Inverse gas chromatography	81
3.5.	Conclusions	85
4.	<u>Influence of solvent on the morphology and subsequent comminution of ibuprofen crystals by air jet milling</u>	
4.1.	Introduction	88
4.2.	Materials	90
4.3.	Methods	90
4.3.1.	Crystallisation procedure for ibuprofen	90
4.3.2.	Cooling crystallisation	92
4.3.3.	Sieving	93

4.3.4.	Micronisation	93
4.3.5.	Powder avalanche testing	95
4.3.6.	Molecular modelling	95
4.3.7.	Dissolution studies	96
4.3.8.	HPLC analysis	96
4.4.	Results and discussions	97
4.4.1.	Crystallisation studies and particle morphology	97
4.4.2.	Thermal and structural analysis	97
4.4.3.	Particle size distribution	102
4.4.4.	Surface analysis	
4.4.4.1.	Inverse gas chromatography (IGC)	106
4.4.5.	Dissolution study	110
4.4.6.	Morphological importance of ibuprofen for size reduction	112
4.5.	Conclusions	122
5.	<u>Effect of crystallisation conditions and feedstock morphology on the aerosolisation performance of micronised salbutamol sulphate (SS)</u>	
5.1.	Introduction	125
5.2.	Materials	126
5.3.	Methods	126
5.3.1.	Crystallisation procedure of SS	125
5.3.2.	Sieving	128
5.3.3.	Micronisation	128
5.3.4.	Molecular modelling	130
5.3.5.	Particle size analysis	130
5.3.6.	Twin stage liquid impinger	131
5.3.7.	Andersen cascade impactor	132
5.3.8.	Aerosolisation stability study of SS	133

5.3.9. UV analysis	134
5.4. Results and discussions	134
5.4.1. Effect of cooling and stirring rate on the morphology of SS	134
5.4.2. Effect of crystallisation conditions on solid surface chemistry of SS	137
5.4.3. Thermal and structural analysis	138
5.4.4. Particle size distribution	142
5.4.5. Surface analysis	146
5.4.5.1. Dynamic vapour sorption (DVS)	146
5.4.5.2. Inverse gas chromatography (IGC)	150
5.4.6. In-vitro aerosolisation study of SS	154
5.4.7. Aerosolisation stability study for SS	157
5.5. Conclusions	160
6. <u>Towards a rapid method for predicting the mechanical behaviour of active pharmaceutical ingredients</u>	
6.1. Introduction	163
6.2. Materials	166
6.3. Methods	167
6.3.1. Molecular modelling	167
6.3.2. Micronisation	170
6.3.3. Brittleness index	171
6.3.4. Anisotropic and isotropic materials	172
6.4. Results and discussions	173
6.5. Conclusions	193
7. <u>General discussion and Future work</u>	
7.1. Introduction	195
7.2. General background, materials and methods used in this thesis	195
7.3. Major findings from studies with alpha lactose monohydrate	196
7.4. Major findings from studies with ibuprofen	198
7.5. Major findings from studies with salbutamol sulphate	201
7.6. A rapid method for predicting the processing behaviour of pharmaceuticals	207

7.7. Conclusions	209
7.8. Future work	212
<u>References</u>	214
<u>Appendices</u>	
Appendix A	226
Appendix B	227
Appendix C	228
Appendix D	228
Appendix E	229
Appendix F	230
Appendix G	231
Appendix H	232

List of Tables

Table 1.1 Different types of dry mills used for particle size reduction of pharmaceutical powders.

Table 3.1 The values of GP, IP and FR used during micronisation of SV003, SV010 and L-Dcrit.

Table 3.2 High and low values of GP, IP and FR used during micronisation of SV003, SV010 and L-Dcrit.

Table 3.3 Median particle size (D50) and polydispersity for micronised batches of SV003, SV010 and L-dcrit.

Table 3.4 Percentage crystallinity for micronised batches of SV010, SV003 and L-Dcrit.

Table 3.5 Dispersive and specific surface free energy for starting and micronised batches of three grades of lactose monohydrate.

Table 4.1 Solubility of ibuprofen in ethanol and hexane at different temperature.

Table 4.2 Sample code for starting ibuprofen material with different morphology and sieve fractions.

Table 4.3 Sample code for the micronised batches of ibuprofen.

Table 4.4 Particle size distribution data for the batches micronised from Et-Ibu and Hx-Ibu starting material using similar processing condition.

Table 4.5 Dispersive and specific surface free energy for starting and micronised batches of ibuprofen.

Table 4.6 Volume mean diameter and specific surface free energy for the batches micronised from Et-Ibu and Hx-Ibu crystals and C-Ibu.

Table 4.7 Crystallisation conditions, temperature differences and surface free energy for ibuprofen crystallised in two different sized vessel using hexane as solvent.

Table 4.8 Particle size distribution and surface free energy data for the micronised batches of Hx-Ibu crystals produced from two different sized vessels.

Table 4.9 Relative facet area and attachment energies of the major crystal faces of ibuprofen calculated using Materials Studio 4.1.

Table 5.1 Crystallisation conditions used for salbutamol sulphate.

Table 5.2 Sample code for the micronised batches of SS.

Table 5.3 Stability conditions and sample code used for SS4 -1 micronised powder samples.

Table 5.4 Moisture adsorption and surface free energy data of starting material SS1, SS2 and SS3.

Table 5.5 Particle size distribution data for micronised batches of SS1, SS2 and SS3.

Table 5.6 Percentage crystallinity data for the batches micronised from SS1, SS2 and SS3.

Table 5.7 Dispersive and specific surface free energy for the starting and micronised batches of SS1, SS2 and SS3.

Table 5.8 Volume mean diameter, % crystallinity, dispersive surface free energy and in-vitro study data of micronised batches of SS1, SS2, SS3 and two supplied generic micronised powder.

Table 5.9 Volume mean diameter, % crystallinity and in-vitro study data of micronised batches of SS4-1 samples stored under different conditions.

Table 6.1 Crystal and mechanical properties for a range of pharmaceutical compounds.

Table 6.2 Particle size distribution data for the micronised batches of ibuprofen, lactose monohydrate, salbutamol sulphate and paracetamol powders.

Table 6.3 Critical stress intensity factor measured using different methods for sucrose and paracetamol.

List of Figures

Figure 1.1 Types of stresses in mills; a) compression, b) shear (attrition), c) impact (stroke) and d) impact (collision).

Figure 1.2 A stress / strain curve for a plastic material.

Figure 1.3 Schematic representations showing the effect of particle size on fracture strength.

Figure 1.4 Point defects of crystals, A - interstitial impurity, B - substitutional impurity and C – vacancy.

Figure 1.5 a) Edge and b) screw dislocations of crystals.

Figure 1.6 The saturation-supersaturation graph.

Figure 1.7 Different types of nucleation.

Figure 1.8 Structured and systematic approach to achieve optimised micronised substances.

Figure 1.9 Chemical structure of alpha lactose monohydrate.

Figure 1.10 Chemical structure of ibuprofen.

Figure 1.11 Chemical structure of salbutamol sulphate.

Figure 2.1 A spiral jetmill.

Figure 2.2 Schematic diagram of DSC.

Figure 2.3 Powder x-ray diffraction from two planes of atom.

Figure 2.4 Dynamic vapour sorption analyser.

Figure 2.5 Schematic diagram showing the determination of the specific component of surface free energy.

Figure 3.1 Schematic diagram of a spiral Jetmill.

Figure 3.2 DSC data showing thermal characteristics for the starting L-Dcrit, SV010 and SV003 at 10^0 C/min scan rate.

Figure 3.3 DSC data showing thermal characteristics for the micronised batches of L-Dcrit, SV010 and SV003 manufactured at the (- + -) processing condition at 10^0 C/min scan rate.

Figure 3.4 DSC data showing the double endothermic event for micronised batches (+ + -) of SV010, SV003 and starting L-Dcrit at 10^0 C/min scan rate.

Figure 3.5 Dehydration onset data for starting material and average DOT of all micronised batches of SV010, SV003 and L-Dcrit determined by TGA at 10^0 C/min scan rate.

Figure 3.6 TGA data showing the effect of particle size fraction on dehydration onset temperature for SV010 at 10⁰ C/min scan rate.

Figure 3.7 Relationship between particle size (sieve fractions of SV010) and dehydration onset temperature determined by TGA at 10⁰ C/min scan rate.

Figure 3.8 Relationship between particle size (sieve fractions of SV010) and dehydration peak temperature determined by DSC at 10⁰ C/min scan rate.

Figure 3.9 PXRD data showing no physical form transformation for the micronised batches (- + -) of SV010, SV003, L-Dcrit and starting L-Dcrit material.

Figure 3.10 Theoretical PXRD pattern of alpha lactose monohydrate.

Figure 3.11 Scanning electron micrographs of a) SV003 (mag. = 500X. Scale= 50.0 μm) and b) SV003 (+ - -) (mag.= 5000X. Scale= 5.0 μm).

Figure 3.12 Effects of starting material particle size on median particle size (D50) for micronised batches of SV010, SV003 and L-Dcrit.

Figure 3.13 A flow diagram for calculating the effect of processing condition shown in pareto chart.

Figure 3.14 Effect of grinding pressure on median particle size (D50) for micronised batches of SV010, SV003 and L-Dcrit.

Figure 3.15 Calibration curve used to calculate the relative percentage crystallinity for micronised batches of SV010, SV003 and L-Dcrit.

Figure 3.16 Average percentage crystallinity for micronised batches of SV010, SV003 and L-Dcrit.

Figure 3.17 Effect of grinding pressure (GP) on percentage crystallinity for micronised batches of SV010, SV003 and L-Dcrit.

Figure 3.18 Effect of starting material median particle size on average specific surface free energy measured using THF for the micronised batches of SV010, SV003 and L-Dcrit.

Figure 3.19 Effect of grinding pressure (GP) on specific surface free energy measured using THF for micronised batches of SV010, SV003 and L-Dcrit.

Figure 3.20 Effect of injector pressure (IP) on specific surface free energy measured using THF for micronised batches of SV010, SV003 and L-Dcrit.

Figure 4.1 Schematic diagram of larger sized crystalliser used in this study with chiller unit.

Figure 4.2 SEM photomicrographs of Et-Ibu and Hx-Ibu crystals respectively.

Figure 4.3 DSC thermograph for the starting and micronised batches of ibuprofen at 10⁰ C/min scan rate.

Figure 4.4 TGA thermograph for the starting and micronised batches of ibuprofen at 10⁰ C/min scan rate.

Figure 4.5 PXRD data for starting and micronised batches of ibuprofen.

Figure 4.6 Theoretical PXRD pattern for ibuprofen.

Figure 4.7 Effect of grinding pressure on volume mean diameter of micronised ibuprofen batches.

Figure 4.8 Effect of grinding pressure on dispersive surface free energy of batches micronised from two different morphology of ibuprofen crystals.

Figure 4.9 Effect of starting material particle size on specific surface energy of the micronised batches of ibuprofen measured using THF.

Figure 4.10 Dissolution data for C-Ibu and micronised batches of ibuprofen.

Figure 4.11 Two unsieved batches of Hx-Ibu crystals produced from a) small sized (Hx-S1) and b) large sized (Hx-S1L) crystallisation vessel.

Figure 4.12 SEM photomicrographs showing crystal defects of Hx-S1L crystals.

Figure 4.13 TGA thermograph for the large and small Hx-Ibu crystals produced from larger sized (3L) and small (1L) sized crystallizer respectively.

Figure 4.14 Schematic representations of different sized Et-Ibu crystals, showing particle size reduction through different mechanisms.

Figure 4.15 SEM photomicrographs for the batches micronised from a) Et-S1 and b) Et-S2 crystals, showing particle size reduction through different mechanisms.

Figure 4.16 a) Schematic representation of Hx-Ibu crystals with proposed fracture pattern b) SEM photomicrographs for micronised Hx-M4 crystals.

Figure 4.17 Molecular orientation of the main crystal faces of ibuprofen.

Figure 4.18 Simulated morphology of ibuprofen generated using Materials Studio 4.1.

Figure 4.19 (100) face showing proposed fracture pattern during particle size reduction through the slip plane.

Figure 5.1 Schematic representation of the Aerolizer device.

Figure 5.2 SEM photographs of three salbutamol sulphate batches- a) SS1, b) SS2 and c) SS3 respectively.

Figure 5.3 Predicted major habit faces of salbutamol sulphate crystals.

Figure 5.4 SEM photomicrographs showing defects a) (mag. 5000 X) and b) (mag. 10000 X) for SS2 crystals.

Figure 5.5 Molecular orientation of the main crystal faces of salbutamol sulphate crystals.

Figure 5.6 DSC data for the starting salbutamol sulphate (SS1) crystals at 10⁰ C/min scan rate.

Figure 5.7 DSC data for the micronised batches of SS1, SS2 and SS3 at 10⁰ C/min scan rate.

Figure 5.8 TGA data for the micronised batches of SS2-1, SS3-1 and SS1-1 at 10⁰ C/min scan rate.

Figure 5.9 Theoretical PXRD pattern for salbutamol sulphate.

Figure 5.10 PXRD data for the starting materials SS1, SS2, SS3 and micronised SS2-1.

Figure 5.11 SEM photomicrographs of a) SS3 - 1 (mag. – 5000X).

Figure 5.12 Effect of feed rate on volume mean diameter observed for micronised batches of SS1, SS2 and SS3.

Figure 5.13 Sorption data measured by DVS for a) freshly micronised SS3-1 b) freshly micronised SS2-1 c) micronised SS2-1 after four months storage in closed vial.

Figure 5.14 PXRD data for the starting material SS2, micronised SS2-1 and stored micronised batch SS2-1 in condition 1.

Figure 5.15 Effect of starting material particle size on dispersive surface free energy observed for micronised batches of SS1, SS2 and SS3.

Figure 5.16 Relationship between a) volume mean diameter and % emitted dose and b) dispersive surface energy and % FPF for micronised salbutamol sulphate.

Figure 5.17 SEM photomicrographs showing aggregates of micronised SS2-1 a) SS2-1 (magnification- 1300X) and b) SS2- 1 (magnification- 80X).

Figure 5.18 ACI drug deposition patterns of SS2-1 and Generic A.

Figure 5.19 SEM photomicrographs of micronised SS4-1 (mag.- 5000X).

Figure 5.20 Sorption data measured by DVS for a) SS4-1 freshly micronised and b) SS4-1 after 1 month in condition 1.

Figure 6.1 Molecular structures of all materials.

Figure 6.2 Flow diagrams for identification of weakly interacting slip planes using crystal attachment energies.

Figure 6.3 Attachment energy versus brittleness index .

Figure 6.4 Slip plane energy versus brittleness index 1.

Figure 6.5 Slip plane energy versus brittle-ductile transition size .

Figure 6.6 Slip plane energy versus hardness value.

Figure 6.7 Crystal structures without discernable slip planes a) lactose monohydrate b) sulfathiazole and c) sucrose.

Figure 6.8 Crystal structures with less deformable slip plane a) Paracetamol - 2 (monoclinic) b) Aspirin form I (monoclinic) c) ibuprofen and d) Tolbutamide.

Figure 6.9 Crystal structures with easily deformable slip plane of a) Aspirin (form II – orthorhombic) b) adipic acid c) caffeine d) Paracetamol - 1 (orthorhombic) e) Phenacetin f) sulfadiazine and g) Theophylline.

Figure 6.10 Highest d-spacing versus brittleness index 1.

Figure 6.11 Highest d-spacing versus brittleness index 2.

Figure 6.12 Dispersive surface free energy versus highest d-spacing.

Figure 6.13 Dispersive surface energy versus brittleness index 2.

Figure 6.14 Highest d-spacings versus median particle size.

Units, symbols and abbreviations

SI Units

C	Centigrade
cal	Calorie
g	Gram
J	Joule
l	Litre
m	Metre
mol	Mole
Pa	Pascale
s	Second
T	Temperature

Prefix used with SI units

k	kilo
m	milli
m	milli
M	mega
μ	micro

Symbols

CHCl ₃	chloroform
d_{hkl}	Spacing between crystal planes
E^{att}	Attachment energy
H	Hardness
K_{ICO}	critical stress intensity factor
min	minutes
R_{hkl}	Relative growth rate
THF	Tetrahydrofuran
Å	Angstrom
θ	angle of X-ray beam diffraction
σ_{ym}	Modified yield stress
γ_{hkl}	specific surface energy

Abbreviations

API	Active pharmaceutical ingredients
BCF	Barton, Cabrera and Frank crystal growth model
BFDH	Bravais-Friedel-Donney-Harker
CCDC	Cambridge Crystallographic Data Centre
CSD	Cambridge structural database
DSC	Differential scanning calorimetry
DPI	Dry powder inhaler
DVS	Dynamic vapour sorption
D50	Median particle size

Et-Ibu	Ibuprofen crystallised from ethanol
ED	Emitted dose
FID	Flame ionization detector
FPF	Fine particle fraction
FPD	Fine particle dose
FR	Feed rate
GP	Grinding pressure
HPLC	High-performance liquid chromatography
Hx-Ibu	Ibuprofen crystallised from hexane
IGC	Inverse gas chromatography
IP	Injector pressure
IPA	Iso-propyl alcohol
Mag	Magnification
PDI	Polydispersity index
PXRD	Powder X-ray diffractometry
RD	Recovered dose
rpm	Rotation per minute
RH	Relative humidity
SS	Salbutamol sulphate
SEM	Scanning electron microscopy
TSLI	Twin stage liquid impinge
UV	Ultraviolet
VMD	Volume mean diameter
d_{crit}	Critical particle size (diameter)
0D	Absence of hydrogen bonding
1D	One dimension hydrogen bonding
2D	Two dimension hydrogen bonding
3D	Three dimension hydrogen bonding